Literature DB >> 34711337

Matrix-Degrading Enzyme Expression and Aortic Fibrosis During Continuous-Flow Left Ventricular Mechanical Support.

Amrut V Ambardekar1, Matthew S Stratton2, Evgenia Dobrinskikh3, Kendall S Hunter4, Philip D Tatman5, Madeleine E Lemieux6, Joseph C Cleveland7, Rubin M Tuder3, Mary C M Weiser-Evans8, Karen S Moulton2, Timothy A McKinsey2.   

Abstract

BACKGROUND: The effects of nonphysiological flow generated by continuous-flow (CF) left ventricular assist devices (LVADs) on the aorta remain poorly understood.
OBJECTIVES: The authors sought to quantify indexes of fibrosis and determine the molecular signature of post-CF-LVAD vascular remodeling.
METHODS: Paired aortic tissue was collected at CF-LVAD implant and subsequently at transplant from 22 patients. Aortic wall morphometry and fibrillar collagen content (a measure of fibrosis) was quantified. In addition, whole-transcriptome profiling by RNA sequencing and follow-up immunohistochemistry were performed to evaluate CF-LVAD-mediated changes in aortic mRNA and protein expression.
RESULTS: The mean age was 52 ± 12 years, with a mean duration of CF-LVAD of 224 ± 193 days (range 45-798 days). There was a significant increase in the thickness of the collagen-rich adventitial layer from 218 ± 110 μm pre-LVAD to 410 ± 209 μm post-LVAD (P < 0.01). Furthermore, there was an increase in intimal and medial mean fibrillar collagen intensity from 22 ± 11 a.u. pre-LVAD to 41 ± 24 a.u. post-LVAD (P < 0.0001). The magnitude of this increase in fibrosis was greater among patients with longer durations of CF-LVAD support. CF-LVAD led to profound down-regulation in expression of extracellular matrix-degrading enzymes, such as matrix metalloproteinase-19 and ADAMTS4, whereas no evidence of fibroblast activation was noted.
CONCLUSIONS: There is aortic remodeling and fibrosis after CF-LVAD that correlates with the duration of support. This fibrosis is due, at least in part, to suppression of extracellular matrix-degrading enzyme expression. Further research is needed to examine the contribution of nonphysiological flow patterns on vascular function and whether modulation of pulsatility may improve vascular remodeling and long-term outcomes.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aorta; congestive heart failure; fibrosis; left ventricular assist device; mechanical circulatory support; vascular remodeling

Mesh:

Substances:

Year:  2021        PMID: 34711337      PMCID: PMC8562886          DOI: 10.1016/j.jacc.2021.08.047

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

2.  Dynamic Changes in Aortic Vascular Stiffness in Patients Bridged to Transplant With Continuous-Flow Left Ventricular Assist Devices.

Authors:  Amit C Patel; R Blair Dodson; William K Cornwell; Kendall S Hunter; Joseph C Cleveland; Andreas Brieke; JoAnn Lindenfeld; Amrut V Ambardekar
Journal:  JACC Heart Fail       Date:  2017-03-08       Impact factor: 12.035

3.  Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis.

Authors:  Hiroe Toba; Presley L Cannon; Andriy Yabluchanskiy; Rugmani Padmanabhan Iyer; Jeanine D'Armiento; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-23       Impact factor: 4.733

Review 4.  Epigenetics and vascular diseases.

Authors:  Matthew S Stratton; Floriana Maria Farina; Leonardo Elia
Journal:  J Mol Cell Cardiol       Date:  2019-06-15       Impact factor: 5.000

5.  Living Without a Pulse: The Vascular Implications of Continuous-Flow Left Ventricular Assist Devices.

Authors:  Suneet N Purohit; William K Cornwell; Jay D Pal; JoAnn Lindenfeld; Amrut V Ambardekar
Journal:  Circ Heart Fail       Date:  2018-06       Impact factor: 8.790

6.  Neurohormonal regulation and improvement in blood glucose control: reduction of insulin requirement in patients with a nonpulsatile ventricular assist device.

Authors:  Michael M Koerner; Aly El-Banayosy; Kimber Eleuteri; Christina Kline; Edward Stephenson; Walter Pae; Ali Ghodsizad
Journal:  Heart Surg Forum       Date:  2014-04       Impact factor: 0.676

7.  LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis.

Authors:  Zhen Tian; Yu Sun; Xin Sun; Jing Wang; Tao Jiang
Journal:  Eur J Pharmacol       Date:  2020-01-16       Impact factor: 4.432

Review 8.  Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process.

Authors:  Stefan Klotz; A H Jan Danser; Daniel Burkhoff
Journal:  Prog Biophys Mol Biol       Date:  2008-02-12       Impact factor: 3.667

9.  Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing.

Authors:  C Voellenkle; J M Garcia-Manteiga; S Pedrotti; A Perfetti; I De Toma; D Da Silva; B Maimone; S Greco; P Fasanaro; P Creo; G Zaccagnini; C Gaetano; F Martelli
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

10.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.